Fidelity Investments’s MAIA Biotechnology MAIA Stock Holding History

Fidelity Investments’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$2	–	5663
2026 Q1	$2	Buy	+2	New	+$4	﹤0.01%	5403

Other funds holding MAIA

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments's MAIA Position: Q2 2026 in Review

Fidelity Investments sold out of MAIA Biotechnology (MAIA) in Q2 2026, closing a stake of 2 shares — an estimated $2 sold.

Fidelity Investments first reported a position in MAIA in Q1 2026 and held it in 1 quarter. The position peaked at $2 in Q1 2026. 36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

Fidelity Investments reported no remaining MAIA Biotechnology position as of Q2 2026 after selling out during the quarter.
Fidelity Investments sold 2 MAIA Biotechnology shares in Q2 2026, an estimated $2.
Fidelity Investments first reported a position in MAIA Biotechnology in Q1 2026 and held it in 1 quarter.
Fidelity Investments's MAIA Biotechnology position peaked at $2 in Q1 2026.
36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.